Fibrobiologics Inc Expands Fibroblast Platform to Target Hantavirus

Published: 2026-05-11 14:35:52 ET FBLG

Published on 05/11/2026 at 02:35 pm EDT

FibroBiologics, Inc. announced a strategic expansion of its fibroblast-based platform to target Hantavirus. Building on existing preclinical work in treating acute respiratory distress syndrome (ARDS), the major cause of lethality in COVID-19 patients, FibroBiologics is expanding its therapeutic platform to encompass Hantavirus pulmonary syndrome (HPS), which causes similar terminal lung damage and inflammatory cascade as severe COVID-related ARDS. HPS is a rare but severe respiratory illness generally transmitted through contact with infected rodents.

The disease progresses rapidly, causing severe pulmonary edema and multi-organ failure, with mortality rates exceeding 35-40%, even in clinical settings. Currently, there are no approved antiviral therapies or disease-modifying treatments for HPS, leaving patients dependent on supportive care. The pathophysiology of HPS involves uncontrolled inflammatory responses, endothelial barrier dysfunction, and progressive pulmonary fibrosis, mechanisms that FibroBiologics' fibroblast platform is specifically designed to modulate.

Patients surviving acute HPS frequently develop chronic complications including pulmonary fibrosis, reduced lung capacity, and long-term respiratory impairment. Preclinical studies in ARDS models have demonstrated that fibroblasts can reduce excessive inflammatory signaling, restore endothelial barrier integrity, and promote tissue repair, precisely the pathogenic processes that characterize severe Hantavirus disease. The terminal lung damage observed in critical HPS cases mirrors the acute respiratory failure seen in ARDS, making FibroBiologics' fibroblast platform uniquely positioned to address this unmet need.

The company is now evaluating its fibroblast platform in Hantavirus disease models, with particular emphasis on inflammatory cytokine modulation and endothelial permeability reduction. The company plans to initiate exploratory discussions with regulatory authorities to establish a development pathway toward clinical evaluation in HPS patients.